Clinical Trials Logo

Metastatic Bladder Cancer clinical trials

View clinical trials related to Metastatic Bladder Cancer.

Filter by:

NCT ID: NCT01814150 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel

Start date: April 2013
Phase: N/A
Study type: Observational

Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer. One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein. Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in cancer patients. The investigators aim to prospectively study the association between the plasma level of alpha 1 acid glycoprotein and the outcome of docetaxel based therapy in cancer patients.

NCT ID: NCT01454089 Completed - Urologic Neoplasms Clinical Trials

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.